

Supplemental Approvals

Generic Name (Trade Name—Company)

July 9, 2018

Encorafenib, binimetinib

(*Braftovi, Mektovi*—Array BioPharma)

Agents approved in combination for unresectable or metastatic melanoma with BRAF mutations

Uses/Notes

FDA approved [encorafenib and binimetinib](#) in combination for patients with unresectable or metastatic melanoma with a *BRAF* V600E or V600K mutation, as detected by an FDA-approved test.

Approval was based on a randomized, active-controlled, open-label, multicenter trial in 577 patients with *BRAF* V600E or V600K mutation-positive unresectable or metastatic melanoma. Patients were randomized (1:1:1) to receive binimetinib 45 mg twice daily plus encorafenib 450 mg once daily, encorafenib 300 mg once daily, or vemurafenib 960 mg twice daily. Treatment continued until disease progression or unacceptable toxicity.

The major efficacy measure was progression-free survival (PFS) using RECIST 1.1 response criteria and assessed by blinded independent central review. The median PFS was 14.9 months for patients receiving binimetinib plus encorafenib and 7.3 months for the vemurafenib monotherapy arm (hazard ratio 0.54 [95% CI 0.41–0.71], *P*

The most common (>25%) adverse reactions in patients receiving the combination were fatigue, nausea, diarrhea, vomiting, abdominal pain, and arthralgia. Discontinuation of therapy due to adverse reactions occurred in 5% of patients receiving the combination; the most common reasons were hemorrhage and headache.

FDA also granted approval of the THxID BRAF Kit (bioMérieux) as a companion diagnostic for these therapeutics.

The recommended doses are binimetinib 45 mg orally twice daily and encorafenib 450 mg orally once daily.

Source URL:

<http://aphadruginfoline.com/supplemental-approvals/agents-approved-combination-unresectable-or-metastatic-melanoma-braf>

Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.